Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

The genetically modified animal model could lead to new treatments for the global disease Lauren Rust, Ph.D., assistant staff ...

While patient education is a key component of helping link those with HBV to solutions, global collaboration across ... Hepatitis Alliance to examine the burden of CHB globally and provide ...

The burden of chronic hepatitis mostly affects resource-limited countries. HBV vaccination coverage must be improved. Awareness, education, training and screening are needed. A better global and ...

Vaccination against HBV began 30 years ago with availability of plasma-derived, inactivated HBsAg vaccines. Soon after, recombinant HBsAg expressed in yeast cells led to the production of vaccines ...

With its robust clinical pipeline and determined defense of its intellectual property, Arbutus is poised to make significant strides this year in its mission to address the global burden of cHBV.

Hepatitis B and liver cancer are significant global public health challenges. Hepatitis B virus (HBV) infection is a leading risk factor for liver cancer, particularly HCC. Globally, an estimated ...

The company is also seeking global pharmaceutical partners for further codevelopment of hzVSF for HBV and an expanded range of viral diseases, especially as data come in from phase 2 trials.

Hepatitis B and liver cancer are significant global public health challenges. Hepatitis B virus (HBV) infection is a leading risk factor for liver cancer, particularly HCC. Globally, an estimated 296 ...

SINGAPORE, Feb. 11, 2025 /PRNewswire/ -- On 12 Feb 2025 (Singapore Time), Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance ...